Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Insmed Inc (INSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10027)・商品コード:DATA904C10027
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:43
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are being developed for pulmonary arterial hypertension (PAH), severe refractory asthma, for chronic inflammatory lung diseases such as non-cystic fibrosis (non-CF) bronchiectasis and for nontuberculous mycobacterial lung infection and chronic Pseudomonas aeruginosa in non-CF bronchiectasis. The company has offices in the US, the UK, Ireland, the Netherlands, Germany and France. Insmed is headquartered in Bridgewater, New Jersey, the US.

Insmed Inc (INSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9
Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Insmed Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11
Licensing Agreements 12
Insmed Enters into Licensing Agreement with AstraZeneca 12
Premacure Amends Licensing Agreement with Insmed 14
Equity Offering 15
Insmed Raises USD402 Million in Public Offering of Shares 15
Insmed Raises USD237.4 Million in Public Offering of Common Stock 17
Insmed Raises USD115 Million in Public Offering of Shares 19
Insmed Completes Public Offering Of Shares For US$71.8 Million 21
Insmed Completes Public Offering Of Common Stock For US$26 Million 23
Debt Offering 24
Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24
Insmed Inc – Key Competitors 26
Insmed Inc – Key Employees 27
Insmed Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Oct 30, 2018: Insmed reports third quarter 2018 financial results and provides business update 29
Aug 02, 2018: Insmed reports second quarter 2018 financial Results and provides business update 31
May 02, 2018: Insmed Reports First Quarter 2018 Financial Results and Provides Business Update 33
Feb 23, 2018: Insmed Reports Fourth Quarter 2017 Financial Results 34
Nov 02, 2017: Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update 36
Aug 03, 2017: Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update 37
May 03, 2017: Insmed Reports First Quarter 2017 Financial Results 38
May 03, 2017: Insmed Q1 net loss increases 39
Feb 23, 2017: Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update 40
Corporate Communications 41
May 15, 2017: Insmed Announces Key Additions to its Executive Management Team 41
Clinical Trials 42
May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Insmed Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9
Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11
Insmed Enters into Licensing Agreement with AstraZeneca 12
Premacure Amends Licensing Agreement with Insmed 14
Insmed Raises USD402 Million in Public Offering of Shares 15
Insmed Raises USD237.4 Million in Public Offering of Common Stock 17
Insmed Raises USD115 Million in Public Offering of Shares 19
Insmed Completes Public Offering Of Shares For US$71.8 Million 21
Insmed Completes Public Offering Of Common Stock For US$26 Million 23
Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24
Insmed Inc, Key Competitors 26
Insmed Inc, Key Employees 27
Insmed Inc, Subsidiaries 28

List of Figures
Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10027)販売に関する免責事項を必ずご確認ください。
★調査レポート[Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆